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CHAPTER ONE
INTRODUCTION
Inflammation is the bodies first response to defend itself against foreign pathogens and damage.
Cellular sensors are constantly monitoring the body and checking for homeostatic disruption. Microbial
pathogens and tissue damage are sensed by pattern recognition receptors (PRRs), which sense pathogen
associated molecular patterns and damage associated molecular patterns, termed PAMPs and DAMPs
respectively. Within the family of PRRs are sensors that can induce the formation of the multi-protein
complex termed the inflammasome following activation. The inflammasome complex is a molecular
platform for which caspase 1, a cysteine protease, is incorporated and is responsible for the maturation of
pro-inflammatory cytokines such as IL-1B and IL-18. These mature cytokines are then released from the
cell and act via endocrine and paracrine signaling to generate an inflammatory environment. Among these
cytokines, other cellular substrates are targeted and cleaved by active caspase 1, such as the protein
gasdermin D. Cleavage of gasdermin D can lead to a form of programmed cell death termed pyroptosis, a
highly inflammatory cell death. Upon activation, gasdermin D self oligomerizes creating a pore in the cell
wall. This allows for the secretion of massive amounts of inflammatory cytokines as well as an influx of
water into the cell leading to eventual cell death.
Aberrant inflammation is the cause of a multitude of human diseases, such as Rheumatoid
Arthritis, Systemic Lupus Erythematosus, and Multiple Sclerosis. For some of these inflammatory
disorders, details about the pathophysiology remain a mystery. Therefore, further understanding of these
inflammatory processes is of critical importance. The ability to accurately measure inflammation in vitro,
as well as in vivo, would offer a model to further advance our understanding of the inflammatory
response.
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Biosensors emerged as a unique model to measure these processes both in vitro and in vivo. A
previously published bioluminescent biosensor measuring protease activation has been used effectively
by our lab. This biosensor is a modified version of a firefly luciferase protein, where it has been permuted
to swap the N- and C- terminus. In addition, a linker sequence was inserted between the two halves. This
effectively blocks the proteins ability to fold into its active conformation, and therefore no
bioluminescence can be detected. Within the linker sequence is a protease recognition sequence that is
cleaved by an active protease. Following cleavage, the separated halves of the protein can then fold into
the active formation and bioluminescence can be measured. Our lab has modified the linker sequence to
measure cleavage by activated caspase 1, the active component of inflammasomes, and therefore measure
inflammation. However, while using this biosensor in various experiments in vitro and in vivo, we have
noticed that there were varying levels of activation while using different cell types. There was also a
noticeable difference with various inflammatory stimuli. Because of this, we were able to form a few
different hypotheses around these results. Our hypothesis is that we are seeing some level of substrate
specificity of caspase 1. To investigate this, we first developed a repertoire of biosensors (Aim 1). Using
said biosensors, we investigated if substrate specificity exists within different cell types (Aim 2) or with
different inflammatory stimuli (Aim 3).
Specific Aim 1: Develop various biosensors of different known caspase 1 substrates.
Currently our biosensor measures caspase 7 cleavage, a known caspase 1 target. However,
caspase 7 is also known to be cleaved by apoptotic caspases as well. There are many more known
substrates of caspase 1, each having a unique cleavage sequence. Since this information is already
published, we can identify which proteins are cleaved by caspase 1 and create biosensors that are
activated following cleavage of unique sequences that correspond to different substrates.
Specific Aim 2: Investigate if caspase 1 substrate specificity exists among different cell types within the
body.
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Using THP-1 (monocyte), HaCat (keratinocyte), Chme-5 (microglia), HepG2 (hepatocyte), and
CaCo-2 (intestinal epithelial) cells expressing biosensors, we will quantify biosensor activation in each of
these cells following inflammasome activation. Inflammasomes will be activated in a variety of ways,
including different TLR agonists, dsRNA, and dsDNA. Following inflammasome activation in each cell
type, we can elucidate any differences among caspase 1 protease activity following activation by
measuring differences in bioluminescence.
Specific Aim 3: Investigate if caspase 1 substrate specificity exists following inflammasome activation
with different inflammatory stimuli.
Using THP-1 (monocyte), HaCat (keratinocyte), Chme-5 (microglia), HepG2 (hepatocyte), and
CaCo-2 (intestinal epithelial) cells expressing a biosensor, we can activate the inflammasome with a
variety of inflammatory stimuli. The stimuli will include TLR agonists, dsRNA, dsDNA, bacterial toxins
inducing potassium efflux, drugs inducing vesicular rupture, among others. For each condition,
bioluminescence readout will measure caspase 1 activation and inflammasome activation. Differences
within the same cell type can be uncovered and further investigated.
Impact: Caspase 1 is an essential component of the inflammasome and plays a role in spreading and
maintaining inflammation in the body. A better appreciation of this protease may uncover novel
treatments for those with chronic inflammatory diseases, as well as potentially elucidating the
pathophysiology of various diseases. Caspase 1 biosensors will give us a tool to study caspase 1 and the
inflammasomes to improve our understanding.

CHAPTER TWO
LITERATURE REVIEW
Overview
Inflammasomes are multi-protein complexes responsible for triggering an innate immune
response for pathogen clearance or responding to various stressors. Inflammasomes were first
characterized in 2002 when they discovered a multi-protein complex containing NALP1 (now known as
NLRP1), apoptosis-associated speck-like protein containing a CARD (ASC), and the inflammatory
caspases 1 and 5 (1). This inflammasome was responsible for maturation of IL-1B (1). IL-1B is an
inflammatory cytokine responsible for activating immune responses to pathogens and injury. They found
that the inflammasome was an essential platform for the activation of caspase 1, which is initially
produced as a zymogen. Caspase 1, previously termed IL-1B converting enzyme (ICE), is the protease
incorporated into inflammasomes responsible for maturation of proIL-1B and proIL-18. Release of these
inflammatory cytokines leads to activation of signaling cascades that propagates a local or systemic
inflammatory response for proper clearance of pathogens.
Inflammasomes were first characterized in macrophages but are now appreciated to be present in
a variety of cell types including neurons (2), astrocytes (3), microglia (3), B cells (4), T cells (5),
hepatocytes (6), keratinocytes (7), and intestinal epithelium (8). These cells all contain cytosolic, nuclear
and membrane-associated pattern recognition receptors (PRRs) which can sense pathogen associated
molecular patterns and damage associated molecular patterns, termed PAMPs and DAMPs respectively.
Various cytoplasmic PRRs, such as nod like receptors (NLRs) and AIM2-like receptors (ALRs), can form
inflammasomes following recognition of PAMPs and DAMPs (9). These are termed the canonical
inflammasomes. There is also non-canonical inflammasomes that can be activated following intracellular
4
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LPS detection (10). Following assembly of inflammasomes, inflammatory caspases are also activated.
These caspases are responsible for the cleavage and maturation of various inflammatory cytokines. In
addition, they activate the pyroptotic executioner protein gasdermin D. Gasdermin D, following
activation, oligomerizes and inserts itself into the plasma membrane forming pores, leading to the
eventual programmed cell death termed pyroptosis (11). Pyroptosis is a highly inflammatory cell death as
it releases the intracellular contents of the cell, including high amounts of mature cytokines, into the
extracellular space.
Over the years, further understanding of the role of inflammasomes in inflammation has
implicated them to play a role in chronic inflammatory disorders. There is now evidence that aberrant
inflammasome activation is the direct cause of various human diseases, as well as playing a role in many
others. The roles of inflammasomes in these diseases has made them attractive targets for treatments.
PRRs
Pattern Recognition Receptors (PPRs) are a key component to the cellular innate immune
machinery. They are called PRRs due to their ability to recognize a wide spectrum of common molecular
patterns, either those frequently found from pathogens, termed pathogen-associated molecular patterns
(PAMPs), or endogenous signals indicating cellular harm, termed damage-associated molecular patterns
(DAMPs). PRRs are highly evolutionarily conserved components of the immune response that play roles
in activating the innate immune response (12). They have also been found to be involved in the adaptive
immune response (12). Four main families of PRRs exist: Nucleotide-binding domain (NBD) and
leucine-rich repeat containing protein family (NLR), retinoic acid-inducible gene 1 (RIG-1)-like receptors
(RLRs), C-type lectin receptors (CLRs), and toll-like receptors (TLRs).
NLRs are cytosolic sensors of various PAMPs and DAMPs. They can sense a wide range of
stimuli including pathogen derived, host derived and environmental derived stimuli (13). There are about
20 different known members in this family (13). NLRs all share a common domain, the NOD domain,
also referred to as a NACHT (NAIP, CIITA, HET-E, and TP-2) (14). They can then be split further into
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four subfamilies based on their structure: NLRA, NLRB, NLRC, and NLRP. The NLRA subfamily
contains only one member, CIITA, an MHC-II transactivator. This family has an N-terminal acidic
transactivation domain (AD). The NLRB subfamily also has only one member, NAIP, containing an Nterminal baculoviral inhibitory repeat-like domain (BIR). The NLRC family consists of NOD1, NLRC4,
NOD2, NLRC3, NLRC5, and NLRX1. The subfamily all contains an N-terminal caspase activation and
recognition domain (CARD). The fourth subfamily, NLRP, contain an N-terminal pyrin domain and
consist of NLRP1-14. NLRs have roles in addition to inflammasome formation, such as signal
transduction, transcription activation, and autophagy (15).
RLRs are another type of PRR found in the cell. RIG-I and MDA5 are both examples of RLRs.
These PRRs are responsible for detecting viral dsRNA (16, 17). Following binding of dsRNA, RLRs
become activated and interact with mitochondrial antiviral signaling proteins (MAVS) (16, 17). This
interaction allows for the activation of NF-kB signaling, resulting in production of inflammatory
cytokines such as IL-6 and proIL-1B via activated interferon 1 (IFN1) gene expression. Activation of
these genes allows for signaling to occur through cytokine signaling, creating an inflammatory
environment. This signaling is very important for the hosts ability to clear infected cells through
recruitment of immune cells.
CLRs are a PRR class that is responsible for antiviral activity. CLRs bind to carbohydrate
moieties on viral envelopes (18). Following binding of CLRs to their ligand, internalization of the virus
occurs and can then be degraded either in lysosomes or via autophagy. They are also the most important
PRR for detection of fungi, as several CLRs can recognize components of the fungal cell wall such as Bglucan (Dectin 1), mannans (Dectin 2 and 3), mannoproteins (MR, Mincle, DC-SIGN), and chitin
(unknown) (19).
The fourth subfamily of PRRs are the TLRs. TLRs were the first PRR discovered and are the best
characterized. There are 10 TLRs in humans (TLR1-10) and 13 TLRs in mice (TLR1-13), each of which
is capable of sensing different PAMPs and DAMPs (20). These TLRs activate an immune response
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through the activation of NF-kB signaling, leading to the production of pro-inflammatory cytokines. This
intracellular signaling can be dependent on MyD88 or TRIF signaling. TLRs can be found both at the cell
surface and intracellularly. Those that are found at the cell surface are TLR1, TLR2, TLR4, TLR5, TLR6,
and TLR10 and those that are intracellular are TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13
(21). The cell surface TLRs typically recognize microbial cell wall components such as LPS (TLR4),
flagellin (TLR5), or a wide variety of PAMPs (TLR1, 2, 6). The TLRs found in intracellular
compartments are more responsible for sensing nucleic acids from pathogens such as dsRNA (TLR3),
ssRNA (TLR7), and bacterial 23S rRNA (TLR13).

Figure 1. The Structure of Inflammasomes. Activators of the inflammasomes are listed at the top.
Mouse NLRP1b is activated by B. anthracis Lethal factor. Following activation, ASC binds to NLRP1b
via PYD-PYD interaction. ASC also binds pro-caspase 1 via CARD-CARD interaction. NLRP3 is
activated by a wide range of stimuli and requires ASC to assemble. NLRC4 is activated by flagellin and
components of the T3SS. NLRC4 does not require ASC as it can directly bind caspase 1 via CARDCARD binding. AIM2 binds dsDNA and requires ASC to form. Pyrin recognizes bacterial changes to
host RHO GTPases and requires ASC. The active component of all the inflammasomes is caspase 1,
which cleaves proIL-1B and proIL-18 into their mature forms. In addition, it cleaves gasdermin D,
which can lead to the inflammatory cell death termed pyroptosis. Adapted from Kannegant et al. 2016
(38).
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Inflammasomes
NLRP1
The NLRP1 inflammasome was the first inflammasome to be described (1). Following activation
of caspase 1 by MDP, the researchers found a multi-protein complex containing NLRP1, ASC, and
inflammatory caspases leading to the downstream maturation of IL-1B. We now know that the NLRP1
protein acts as the scaffold for the activation of caspase 1, which is the component responsible for the
maturation of the inflammatory cytokines IL-1B and IL-18. Activation can also lead to the inflammatory
cell death termed pyroptosis, which occurs following caspase 1 cleavage of the protein gasdermin D
(Figure 1, 11).
The NLRP1 inflammasome is unique among the other inflammasomes for a few different reasons.
Firstly, NLRP1 is the only known NLR to contain both a caspase activating and recruitment domain
(CARD), located on the C-terminus, and pyrin domain (PYD), located on the N-terminus (Figure 1, 23,
24). The CARD domain has been shown to be crucial for the activation of caspase 1 through ASC
interactions. The PYD domain, however, has been shown to be dispensable for caspase 1 activation so it
is not well understood what its role is (22). Additionally, there is much genetic diversity of NLRP1
between different species and how the inflammasome assembles. In humans, NLRP1 interacts via CARDCARD interactions with the adapter protein ASC. Following caspase 1 interaction via CARD-CARD
interactions with ASC, the ASC molecules interact via PYD-PYD binding to form the active
inflammasome. In mice, there are three genetic paralogs of NLRP1 (Nlrp1a, Nlrp1b, Nlrp1c), each
lacking the N-terminal PYD domain found in the human variant (23). It has been found that ASC is
dispensable for inflammasome activation. However, it does enhance the signal when present. NLRP1 is
also the only inflammasome to contain a function-to-find domain (FIIND), which has been found to play a
critical role in its activation (22). The FIIND domain undergoes autocatalytic processing to allow for
NLRP1 to reach its active state. This post-translational modification is found in both the human and
mouse variants. The NLRP1 inflammasome has been found to be activated following detection of lethal
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toxin (LT) from Bacillus anthracis, Toxoplasma gondii, muramyl dipeptide (MDP), and intracellular ATP
depletion.
The NLRP1 inflammasome has been implicated in various diseases. There are single nucleotide
polymorphisms (SNPs) located near the NLRP1 gene, generally in non-coding regions, that have been
associated with many diseases, such as Rheumatoid Arthritis, Vitiligo, Crohn’s Disease and more (22). It
is not yet understood how these SNPs may contribute to the onset of disease, but one hypothesis is that
they are somehow effecting transcription of NLRP1. One SNP, M1184V, can lead to increased FIIND
processing and as a result, more IL-1B processing.
NLRP3
The most well studied inflammasome is the NLRP3 inflammasome. This inflammasome is unique
because it is activated by a wide range of PAMPs and DAMPs, encompassing viruses, bacteria, fungi, and
protozoa. Endogenous molecules, such as extracellular ATP, monosodium urate crystals, B-amyloid,
hyaluronan, as well as environmental irritants, such as asbestos, alum, nanoparticles and silica, can
activate the NLRP3 inflammasome. Due to the wide range of stimuli, it is believed that NLRP3 does not
directly interact with the stimuli and is instead the result of a common signaling pathway.
Full activation of the NLRP3 inflammasome requires two signals, a characteristic unique to
NLRP3 (24). The first signal, known as a priming signal, is required for the activation of nuclear
transcription factor kappa B (NF-kB) signaling for increased production of the pro-inflammatory
cytokines proIL-1B and proIL-18 and NLRP3. Other caspase 1 substrates are likely also up-regulated
during priming. Additionally, NLRP3 must undergo post-translational modifications, such as
phosphorylation and ubiquitination, to become activated (24). These modifications to NLRP3 are still not
well understood. A second signal, the activation signal, then leads to the activation of caspase 1, the
assembly of the inflammasome components, and the eventual maturation of the pro-inflammatory
cytokines leading to their secretion from the cell. Requiring extensive protein modifications, cellular
localization, and a dual-signal system are all cellular regulation mechanisms to properly control
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inflammasome activation (24). Following activation, the NLRP3 inflammasome can lead to pyroptosis
following infection with several bacterial species, including Shigella flexneri, Listeria monocytogenes,
Legionella pneumophilla, Yersinia pseudotuburculosis, Pseudomonas aeruginosa, Burkholderia
pseudomallei, and Francisella tularensis.
There are currently thought to be three main paths leading to NLRP3 activation. The first is the
model of potassium efflux. In this model, disruption of membrane potential through the binding of ATP to
the P2X7 receptor or physical damage of the plasma membrane leads to an efflux of potassium and
impaired mitochondrial function. The second model is the reactive oxygen species (ROS) model. In this
model, ROS from the mitochondria directly activate NLRP3. The third model is the cathepsin activation
model. Here, endosomal disruption by crystals or other particles, such as saturated fatty acids, leads to the
release of cathepsin B that activates NLRP3. Despite these described models, it remains poorly
understood if and how these pathways converge to activate NLRP3.
The multi-protein complex that is the NLRP3 inflammasome contains the NLRP3 protein and the
active protease, caspase 1, held together by the adapter protein ASC. ASC binds to NLRP3 via PYD-PYD
interaction and to caspase 1 by CARD-CARD interactions. Additionally, a fourth protein, NIMA-related
kinase 7 (NEK7), acts as a regulator of NLRP3 assembly through NEK7-NLRP3 binding. NEK7 is a
serine-threonine kinase that plays a role in microtubule regulation during mitosis. In a study on traumatic
brain injury, down-regulation of NEK7 activity attenuates NEK7-NLRP3, ASC specks, and NLRP3
activation, ultimately leading to suppressed pro-inflammatory cytokine secretion. Despite being a kinase,
catalytic activity is not required for NEK7 to fulfill its role in aiding NLRP3 oligomerization (24).
Another study has found that in patients with Systemic Lupus Erythematosus (SLE), there was lower
expression levels of NEK7, NLRP3, and ASC compared to healthy controls, suggesting the NEK7NLRP3 complex may play a protective role during SLE.
NLRP3 gain-of-function mutations are the cause of various diseases, such as Muckle-Wells
syndrome (MWS), familial cold-induced auto-inflammatory syndrome (FCAS), and chronic infantile
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neurologic cutaneous articular syndrome (CINCA)/neonatal onset multi-system inflammatory disease
(NOMID). These diseases have been grouped collectively to be referred to as cryopyrin-associated
periodic syndromes (CAPS). Many of these mutations result in signal 2 (activation signal) independent
NLRP3 activation. This leads to hyper-activation of NLRP3 and increased inflammasome assembly.
Presentation of these diseases is similar as they result in chronic inflammatory episodes due to increased
inflammasome activation and inflammatory cytokine release.
NLRC4
NLRC4 is unique in that it lacks a pyrin domain and instead has a CARD domain (Figure 1).
Because of this, the NLRC4 protein does not require the adapter protein ASC to facilitate the assembly of
the inflammasome as NLRC4 can bind pro-caspase 1 via CARD-CARD interaction. ASC, however, has
been found to enhance NLRC4 dependent caspase 1 activation (25). NLRC4 is activated following
detection of PAMPs by NLR family Apoptosis Inhibitory Proteins (NAIPs) (25). Following ligand
binding to NAIPs, it undergoes a conformational change to allow interaction with NLRC4 and facilitates
oligomerization and activation.
The NLRC4 inflammasome is known to play a critical role in defense against enteric bacterial
pathogens and is activated by bacterial flagellin. Multiple bacterial species, such as Pseudomonas
aeruginosa, Legionella pneumophilla, Shigella flexneri, and Salmonella enterica trigger NLRC4
inflammasome dependent IL-1B secretion, despite the fact that species like Shigella lack flagellin (25). It
was later found that certain segments of the Type III secretion system (PrJ-like proteins) could also
activate the inflammasome and that these segments were homologous to flagellin (25). NLRC4 also is a
key component for protection against systemic pathogens. Activating NLRC4 by detection from NAIP
can lead to activation of other inflammasomes such as NLRP3.
NLRC4, like NLRP3, has various cellular regulators that modulate its activity. NLRC4 activation
has been found to be highly regulated at the post-translational level by various modifications, particularly
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phosphorylation by Protein Kinase C (PKC) and Leucine Rich Repeat-containing Kinase-2 (LRRK2) at
serine 533 (26, 27).
The effector protease of the NLRC4, as with the other inflammasomes, is caspase 1. However,
NLRC4 has recently been found to have roles in prostaglandin and leukotriene synthesis, independent of
pro-inflammatory cytokine maturation. The pathway of this process and the roles of NLRC4 and caspase
1 are not well understood. Caspase 1, however, is not the only effector caspase NLRC4 recruits to the
inflammasome. It has been found that caspase 8 is also recruited and activated by the inflammasome (28).
Unlike caspase 1, caspase 8 is a pro-apoptotic protease and in cells deficient for caspase 1 and gasdermin
D, NLRC4 activation has induced caspase 8 dependent apoptosis.
It is becoming increasingly well understood the role of NLRC4 in vitro but the in vivo role of this
inflammasome remains poorly described. It is now appreciated that NLRC4 has a role in autoinflammation. Gain of function mutations of NLRC4 are responsible for development of infantile
enterocolitis and recurrent Macrophage Activation Syndrome (MAS). MAS is a life-threatening syndrome
responsible for the complication of existing rheumatic diseases, such as systemic Juvenile Idiopathic
Arthritis (sJIA), which is a subtype os Systemic Inflammatory Response Syndrome (SIRS).
AIM2
Absent in melanoma 2 (AIM2) and other AIM2-like receptors (ALRs) are structurally defined by
having a HIN domain and a PYD domain (Figure 1). The AIM2 inflammasome is formed following
detection of dsDNA by the HIN domain in the cytoplasm (29). Similar to other inflammasomes, excluding
NLRC4, following activation of AIM2, the protein recruits the adapter protein ASC to interact via PYDPYD binding. ASC, which interacts with caspase 1 via CARD-CARD interactions, facilitates the
incorporation of caspase 1 into the complex that is the AIM2 inflammasome. There is a large genetic
diversity of ALRs, similar to that of NLRs. There are no known orthologs between the 13 mouse ALRs
and 4 human ALRs. Interestingly, there are no ALRs found in bats despite having conserved other innate
immune sensors such as NLRs (30). This may explain why bats make a suitable host to many viruses.
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AIM2 is primarily found within the cytoplasm of cells and is unregulated following interferon
signaling. AIM2 is the main cytoplasmic DNA sensor and directly binds dsDNA following detection.
Upon binding of DNA in the HIN domain, auto-inhibition of the AIM2 protein, via HIN-PYD interaction,
is released and allows activation.
AIM2 detects a wide range of DNA from many different pathogens. Bacterial dsDNA from
species such as Francisella tularensis, Listeria monocytogenes, Streptococcus pneumoniae, Legionella
pneumophila, and Staphylococcus auerus have been found to activate the AIM2 inflammasome. AIM2
can also detect dsDNA from viruses and has been shown to do so for mouse cytomegalovirus, vaccinia
virus, and human papillomavirus. However, the role of AIM2 during the innate immune response during
viral infection is not well understood. Type I interferon has been demonstrated to prime the AIM2
inflammasome and enhance its signaling.
AIM2 can also sense endogenous DNA. Following nuclear envelope disruption, nuclear DNA can
leak into the cytoplasm and be sensed by cytoplasmic DNA sensors, such as AIM2 (31). Interestingly,
AIM2 can also sense DNA damage within the nucleus. Following irradiation of cells, AIM2 can be
activated by sensing double strand breaks and the AIM2 inflammasome can form within the nucleus (32).
Exogenous DNA released in exosomes was also found to be able to activate the AIM2 inflammasome
following uptake by BMDMs (33).
Various mechanisms exist to regulate the activity of the of AIM2 inflammasome. Just like the
other inflammasomes, aberrant activation is problematic and can lead to disease. For AIM2, a key
regulator is lack of ligand availability. Host DNA, under normal circumstances, is compartmentalized
away from where AIM2 can sense its presence. Additionally, there are mechanisms to degrade DNA when
it becomes mislocalized. These mechanisms are displayed when cells lack DNases, allowing for the
accumulation of self-DNA in the cytoplasm. Another mechanism of regulation is the presence of decoy
proteins. These proteins compete with AIM2 and caspase 1 by binding to PYD or CARD domains,
lowering the ability to form the inflammasome. It has also been shown that the AIM2 protein itself can be
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regulated by selective autophagy. Tripartite motif 11 (TRIM11) can directly interact with AIM2 and
trigger its degradation via post-translational modifications. Currently, there have been no gain-of-function
mutations found in AIM2 that are associated with disease. This is thought to be the case because, unlike
NLRP inflammasomes, direct interaction with the target ligand is required for activation.
Pyrin
The pyrin inflammasome is a relatively newly described inflammasome. Pyrin detects changes to
cellular Rho guanosine triphosphatase (Rho GTPase) activity by bacterial toxins. RhoA activity has been
found to be targeted by multiple bacterial species, including Clostridium difficile, Clostridium botulinum,
Bordetella pertussis, Vibrio parahaemolyticus, Histophilus somni, and Burkholderia cenocepacia, leading
to pyrin inflammasome activation.
Pyrin, similar to the other inflammasomes, relies on PYD-PYD interactions with the adapter
protein ASC to incorporate caspase 1 into the active pyrin inflammasome (Figure 1). Pyrin is primarily a
cytosolic sensor. In addition to the N-terminal PYD, pyrin also contains a C-terminal B30.2 domain.
Mutations in this region have been found to result in familial Mediterranean fever (FMF) (34). FMF is an
autosomal recessive inherited disorder. This region has also been shown to directly bind caspase 1 and
modulate IL-1B maturation (34).
Caspase 1
Among the different inflammasomes, the unifying characteristic is the protease caspase 1. Procaspase 1 exists in the cell as an inactive zymogen. It is recruited to the inflammasome platform via
CARD-CARD interactions with the adapter protein ASC. Following incorporation into the
inflammasome, pro-caspase 1 undergoes proximity induced autocatalytic maturation into mature caspase
1.
Caspase 1 is an aspartate specific cysteine protease that cleaves recognized substrates. It's
responsible for the maturation of the pro-inflammatory cytokines IL-1B and IL-18. Additionally, it is
responsible for the cleavage and activation of the pyroptotic executioner protein gasdermin D. However,
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caspase 1 substrate profiles extend much further than these three substrates. There have been more than a
thousand potential substrates identified, demonstrating that caspase 1 is a very promiscuous protease (35).
These substrates have a wide variety of roles in the cell outside of inflammation, including metabolism,
cytoskeleton, signal transduction and more (36).
There are multiple steps needed for caspase 1 activation (Figure 2). Firstly, full length caspase 1
is present in its p46 form in the cell (37). It is then recruited to ASC speck formation in the cell and
incorporated into the inflammasome. Caspase 1 dimerizes and gains some limited proteolytic activity
(37). At this point, caspase 1 has
a limited substrate profile that it
can cleave. Next, it undergoes
proximity induced autocatalytic
maturation into mature p33/p10
caspase 1, gaining full activity
(37). Now, caspase 1’s substrate
profile grows drastically. Caspase
1 regulates its own activity by
Figure 2. Steps to Caspase 1 Activation. 1) Inflammasome
incorporates pro-caspase 1 via ASC. 2) Pro-caspase 1 dimerization.
Dimer has partial activity and processing of certain substrates. 3)
Autocatalytic activation of caspase 1 results in fully active state.
Many more substrates can be processed by caspase 1. 4) Selfcleavage of caspase 1 CARD domain. 5) Release of caspase 1 from
inflammasome, losing activity. Figure adapted from Schroder et al.
2018 (37).

cleaving active p33/p10 into
p20/p10 caspase 1 (37). This
processing removes caspase 1
from its CARD domain,
expelling itself from the

inflammasome complex and losing proteolytic activity.
Biosensors
Biosensors have emerged as fantastic tools to study many different processes in vitro and in vivo.
In our lab, we have developed a caspase 1 biosensor with which we have been able to study inflammation.
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Since caspase 1 is the effector protease in all the inflammasomes, measuring its proteolytic activity is a
great tool for measuring inflammation from a wide variety of stimuli. This biosensor (GloSensor), first
developed in 2013, was designed to measure caspase 3 protease activity in order to measure apoptosis in
vivo (39). This was the basis of the inflammation biosensor that was later developed to measure caspase 1
activity. It is a circularly permuted firefly luciferase construct that is held in an inactive conformation by a
linker sequence (Figure 3). Due to the proteins lack of ability to fold properly, luminescence can not be
detected. Following protease activation, cleavage of the linker sequence allows for proper folding of the
firefly luciferase construct resulting in luminescence that can be measured for quantification of protease
activity.
Our inflammation biosensor contains the cleavage sequence found on caspase 7 within its linker
sequence. Due to caspase 7 being a known caspase 1 substrate, the biosensor has made for an effective
tool to measure caspase 1 activity.

Figure 3. Biosensor Schematic.
Schematic of luciferase biosensor used to
measure inflammation. Biosensor is held
in an inactive conformation and no
luminescence can be detected. Following
caspase 1 activation, cleavage of the
linker sequence allows for folding into
active formation and luminance can be
detected. Adapted from Talley et. al.
2020.

CHAPTER THREE
METHODS
Cell Culture
Cells were incubated at 37˚C in 5% CO2. 293T, HaCaT, HuH7 and Chme-5 cells were cultured in
DMEM supplemented with 10% Fetal Bovine Serum (FBS), 100U/mL penicillin, 100U/mL streptomycin,
and 10 μg/mL ciprofloxacin. HepG2 cells were cultured in RPMI supplemented with 10% FBS, 100U/mL
penicillin, 100U/mL streptomycin, 10 μg/mL ciprofloxacin, 1% non-essential amino acids (NEAA), 1%
HEPES, and 1% sodium pyruvate (NaP). THP-1 cells were cultured in RPMI supplemented with 10%
FBS, 100U/mL penicillin, 100U/mL streptomycin, and 10 μg/mL ciprofloxacin. THP-1 cells were treated
with 100ng/mL PMA for 48hr to induce differentiation into macrophages. BMDMs were cultured in
DMEM with high glucose supplemented with 10% FBS, 100U/mL penicillin, 100U/mL streptomycin, 10
μg/mL ciprofloxacin, 1% non-essential amino acids (NEAA), and 1% HEPES. BMDMs were additionally
given M-CSF (500UI/mL).
293T Transfections and Luciferase Reporter Assay
293T cells were plated at 70% confluence. The cells were then transfected using
polyethylenimine (PEI) with our biosensor plasmid, ASC, and pro-caspase 1. 24hrs later cells were lysed
following treatments with passive lysis buffer. Firefly luciferase substrate was added and luminescence
quantified (RLU) using a luminometer.
Transduction for Production of Stable Cell Lines
Our biosensors were cloned into pLVX. Lentiviral vectors were created using our PEI transaction
protocol with equal parts biosensor, psPAX packaging construct, and vesicular stomatitis virus
glycoprotein (VSVg). After 24hrs, media was changed. 24hrs after the media change, supernatant was
17
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collected, filtered through a 0.45 μM filter. Cells were plated and spinoculated (1,200g for 2hrs @ 13˚C)
with our filtered supernatant containing vector. 48hrs following spinoculation, media was replaced and
5μg/mL puromycin was added for selection.
Inflammasome Activation Assays
Cells were plated in 24 or 48 well plates and stimulated with stimuli and various concentrations
and timing listed. Cells were primed with LPS for 4hrs, followed by signal two for indicated time (Table
1). Lipofectamine was used for transfections with Poly I:C and Poly dA:dT. Supernatant and cell lysates
were collected for luciferase assay.
Table 1. Inflammatory Stimuli. List of the various inflammatory
stimuli used in the following studies with concentrations and timing
of each.
Stimulus

Concentration

Time

LPS

10ng/mL

4h

ATP

5mM/mL

1h

Nigericin

10µM/mL

30m

Poly I:C

100µg/mL

6h

Poly dA:dT

10µg/mL

6h

Pam2CSK4

100ng/mL

6h

Pam3CSK4

100ng/mL

6h

Flagellin

200µg/mL

4h

FSL1

200µg/mL

6h

Curdlan

100µg/mL

6h

MDP

10µg/mL

6h

LLOME

1µM/mL

2h

CHAPTER FOUR
RESULTS
Biosensor Design
Our biosensor used in lab to measure caspase 1 activity is a permuted form of the firefly
luciferase protein. The N- and C-terminus are swapped and held separated by a linker sequence. This
holds the protein in an inactive conformation and luminescence cannot be detected. Within the linker
sequence is a caspase 1 cleavage site that upon cleavage, will separate the protein into two halves and
allow them to fold back into their most energetically favorable state, which is the active state of the
protein. Once refolded, the protein can luminesce and we can quantify this change.
The model of the biosensor used traditionally in our lab measures the cleavage of the pro-caspase
7 protein by active caspase 1. Caspase 7 is a well-established target of caspase 1 and has made for a great
tool for our studies. However, caspase 7 is an apoptotic protein, and measuring inflammation by
quantifying cleavage and activation of an apoptotic protein can raise questions as to whether we are
measuring inflammation or apoptosis. In order to alleviate any doubt, we set out to design a new
biosensor. We decided that gasdermin D, a downstream substrate of caspase 1 and known effector protein
of the inflammatory cell death pyroptosis, would make a good target. Gasdermin D (GSDMD) contains a
different caspase 1 recognition sequence (FLTDGVPA) than caspase 7 (IQADSGPI). We can change our
biosensor by cloning in the gasdermin D sequence instead of the caspase 7 sequence. We first confirmed
the efficacy of the biosensor following transfection into 293T cells. After finding that the biosensor works
well for transfections, we next moved on to create cell lines stably expressing the biosensor. We
transduced THP-1 cells with the biosensor and measured activation following addition of canonical
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stimuli LPS+ATP and LPS+nigericin treatment. We were able to confirm that GSDMD biosensor works
just as well as the C7 biosensor (Figure 4).

Fold Change (Relative to control)

C7 vs GSDMD Biosensor
20

15

10

5

0

NT

LPS + ATP

LPS + Nig

C7

Lipo

Lipo + poly I:C

Lipo + poly dA:dT

GSDMD

Figure 4. C7 vs GSDMD Biosensor. Comparisons between the pro-caspase 7 (C7) biosensor and the
gasdermin D (GSDMD) biosensor in THP-1 cells. Cells were treated with 4h LPS treatment prior to the
addition of ATP or nigericin. Fold change was normalized to no treatment control (NT). Lipofectamine
transfections for delivery of poly I:C and poly dA:dT were normalized to a lipofectamine alone control.
Transfections took place over 6h. The C7 and GSDMD biosensors have similar levels of activation
showing the gasdermin D can make for an effective biosensor.
Substrate Specificity
Previous work done by other lab members found when adding the traditional inflammatory
stimuli, LPS+ATP and LPS+nigericin, to THP-1 cells expressing the C7 biosensor the biosensor turned on
to roughly the same levels for both treatments, which is expected (Figure 5). Interestingly, when repeating
this experiment in C7 transduced MDMs, LPS+nigericin works normally but LPS+ATP seems to not turn
the biosensor on (Figure 5). This experiment was repeated once again but with BMDMs from a C7
transgenic mouse and they found the opposite to be true. LPS+ATP gave a robust biosensor signal but
LPS+nigericin did not activate the biosensor (Figure 5). When repeating these experiments with the
GSDMD biosensor, we found similar results to that seen from C7 (Figure 5). It should be noted that these
experiments could not be repeated with GSDMD in BMDMs due to the lack of a transgenic mouse
expressing the GSDMD biosensor.
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Figure 5. Inflammatory Stimuli/Cell Type May Regulate Caspase 1 Targets. IQAD data, also
known as the C7 biosensor, was previous data completed in lab. THP-1 cells following addition of LPS
+ ATP and LPS + nigericin leads to robust biosensor activation. However, in human MDMs we no
longer see robust activation following LPS + ATP treatment. In BMDMs this robust activation is lost
following LPS + nigericin treatment. These experiments were repeated with the GSDMD biosensor and
found a similar trend in THP-1 and human MDMs. Note that GSDMD could not be tested in BMDMs
as these cells come from a transgenic mouse and we do not have a GSDMD biosensor mouse yet.
Based off of these results, we developed the hypothesis that potentially caspase 1 has some level
of substrate specificity. We thought that maybe caspase 1 isn’t just a promiscuous protease that will cleave
whatever substrate it recognizes, but instead has certain subsets of substrates that it cleaves in different
contexts. After developing the GSDMD biosensor, we figured that we could make more biosensors to
study this hypothesis. Using the same methods as before, we made biosensors for detecting other known
substrates of caspase 1. These included two cleavage sites of proIL-1B, proIL-18, GAPDH, and a
synthetic caspase-1 target sequence (FESD) (Figure 6). Using these new biosensors, the plan was to
transduce different cell types with the different biosensors and check for differing levels of biosensor
activation. If biosensors are being turned on in certain contexts but not in others, this could imply that
potentially caspase 1 is choosing to not cleave them under all contexts.
These experiments were repeated in several cell types including HaCaT (keratinocyte), Chme-5
(microglia), HepG2 (hepatocyte), and CaCo-2 (intestinal epithelial) cells. Each cell type was transduced
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to stably express a different biosensor and various inflammatory stimuli were added to each. Differences
in biosensor activation were monitored. If there was substrate specificity, we would expect that in certain
conditions the biosensor would fully turn on and in others it would turn on to a lesser degree or not at all.
However, this is not what we observed. The biosensors gave similar results for each condition (data not
shown).

New Biosensors

Fold Change (Relative to NT)

30
25
20
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5
0

C7

GSDMD
NT

IL-18
LPS

GAPDH

FESD

LPS+ATP

IL-1B 26

IL-1B 116

LPS+Nig

Figure 6. New Biosensors. New biosensors were tested in THP-1 cells for their levels of
activation following inflammatory insults. All biosensors were activated following treatments and
can be used to effectively monitor caspase 1 activity.
Abbreviations: NT-No Treatment. LPS-Lipopolysaccharide. Nig-Nigericin.
We next wanted to investigate whether substrate specificity stems from a stimulus specific
response. We hypothesized that certain stimuli would trigger caspase 1 to cleave a certain subset of
substrates whereas under different conditions it would cleave another set of substrates. In order to test
this, we limited the amount of biosensors to the GSDMD biosensor activation in different cells. In the
GSDMD THP-1 cells we tested activation from many different inflammatory stimuli. Due to different
stimuli activating varying levels of an inflammatory response, we could only measure whether biosensors
were activated at all and couldn’t make conclusions about different levels of activation. Unfortunately,
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experiments were only able to be conducted on THP-1 cells so comparisons could not be made with other
cell types (Figure 7). Additionally, future experiments could be done with other biosensors, which likely
will add valuable data.
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12.5
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7.5
5

FSL-1+Nig

LPS+FSL-1

FSL-1

Pam3+Nig

Pam3

Pam2+Nig

Pam2

Flag+Nig

LPS+Flag
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Curd+Nig
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GSDMD Biosensor Activation in THP-1 Cells

Figure 7. GSDMD Biosensor Activation in THP-1 Cells. THP-1 cells transduced to stably express
the GSDMD biosensor were treated with various inflammatory components and biosensor activation
was measured by luciferase assay. GSDMD is activated by a diverse range of stimuli.
Abbreviations: NT-No Treatment. LPS-Lipopolysaccharide. Nig-Nigericin. MDP-Muramyl dipeptide.
Curd-Curdlan. Flag-Flagellin. Pam2-Pam2CSK4. Pam3-Pam3CSK4.

CHAPTER FIVE
DISCUSSION
In this study we have developed multiple caspase 1 biosensors that can be used to detect caspase
1 activity in vitro. Caspase 1 activity is a crucial protease to monitor in the context of inflammation due to
it being the active component of all inflammasomes. These biosensors, based off of a previous design
used in our lab, utilize a permuted firefly luciferase protein that is held in an inactive conformation
without luminescence by a linker sequence. Within the linker is a caspase 1 recognition sequence
corresponding to a different known substrate of caspase 1. These biosensors can be used to then detect the
activity of caspase 1 and in the context of this study, measure caspase 1’s ability to cleave a specific
target.
Previously, our lab has utilized a biosensor detecting caspase 1 cleavage of pro-caspase 7’s
sequence. Pro-caspase 7 is a well established substrate of caspase 1 and has been useful for studying
activation of inflammatory responses. However, caspase 7 is an apoptotic protein. We thought that a
biosensor measuring cleavage of a purely inflammatory protein would be beneficial for future studies on
inflammation and better understanding of inflammasomes and caspase 1. To achieve this, we were able to
develop a new biosensor detecting cleavage of gasdermin D’s sequence. Gasdermin D is the executioner
protein of the inflammatory cell death termed pyroptosis.
In this study, we have shown that the GSDMD biosensor is as effective or more effective than the
C7 biosensor in the classical contexts of triggering inflammation in vitro. This includes activating the
inflammasome by LPS pretreatment and activating with ATP or nigericin (Figure 4). It was also tested by
transfecting in poly I:C and poly dA:dT and shown to be just as sensitive as the C7 biosensor (Figure 4).
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In addition, we have shown that the GSDMD biosensor can be activated by a wide range of stimuli
(Figure 7).
Based on previous results in our lab, we found the C7 biosensor to not be activated in situations
where we would anticipate it would be. We were able to recapitulate these results with the GSDMD
biosensor, adding confidence to these findings (Figure 5). We developed the hypothesis that caspase 1 had
some level of substrate specificity. That is, in certain cell types or inflammatory conditions, caspase 1
would target specific substrates and not others. Using the same methods to develop the GSDMD
biosensor, we designed additional biosensors corresponding to various known caspase 1 substrates
(Figure 6). Using these new biosensors, all containing unique cleavage sequences, we had a system in
which we could investigate whether caspase 1 discriminates against cleavage sequences and thus display
some level of substrate specificity.
To investigate substrate specificity, we divided our hypothesis into two sub-aims. Firstly, we
wanted to investigate whether the differences we were seeing was cell type dependent. Since the results
were observed in three different cell types, THP-1, human MDMs, and BMDMs, it seamed plausible that
perhaps caspase 1 has different behaviors in different cell types. In order to investigate this idea, we took
multiple cell types and transduced them with different biosensors. Following the development of stable
cell lines, we induced an inflammatory response in these different cells and measured biosensor levels.
Unfortunately, we did not see significant differences between different cell types (data not shown). We
can not make definitive conclusions from this data, but it does not appear, at least in the cell types tested,
that there are significant differences.
Our second sub aim was to determine if substrate specificity was stimulus dependent. In our
preliminary data, we saw lack of sensitivity between LPS+ATP and LPS+nigericin treatments in some
cell types (Figure 5). To investigate this, we again created a stable cell line expressing our biosensors. We
then added a wide range of inflammatory stimuli and monitored luminescence. Due to some cell types
responding to stimuli more intensely in general, we would not be able to make conclusions based on level
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of biosensor activation. However, we could make conclusions based on whether the biosensor was
activated. We were looking to find that certain stimuli would activate some of the biosensors but not
others. Unfortunately, we were only able to carry this experiment out in THP-1 cells with the GSDMD
biosensor so we could not compare results with other cell types or biosensors. Repeating this experiment
in multiple cell types and more biosensors will allow us to compare the differing levels of activation of
the biosensors and may bring to light interesting differences.
Our results so far do not seem to support the idea of caspase 1 substrate specificity. However, this
should not be ruled out completely quite yet. Despite the lack of evidence of caspase 1 substrate
specificity, many experiments still need to be done to rule out this possibility. Additionally, a new
hypothesis may be that caspase 1 may not care much what substrate is in front of it, but other variables
may be controlling which substrates come into contact with the inflammasome. Potentially, trafficking
proteins can be carrying subsets of substrates to the caspase depending on the situation. Or the opposite
may be occurring, where proteins do not allow for substrates to localize to the inflammasome, effectively
hiding sets of substrates. Further investigation into this idea seems justified as there is still much to be
learned about inflammasome activation, behavior, and host restriction mechanisms.
Additionally, these experiments were all done in vitro. Expanding to an in vivo setting offers
exciting opportunities to further investigate inflammation. Due to the C7 biosensor being well established
to work effectively in vivo, it is plausible that the new biosensors may work as well. Our lab is looking
forward to receiving a new transgenic mouse expressing our GSDMD biosensor in a tissue specific
manner by utilizing the cre-lox expression system. We hope that this will provide a useful model for
further studies of inflammation and auto-inflammation.
It is important to note that despite calling our biosensors “caspase 1 biosensors”, the cleavage
sequences are not exclusively cleaved by caspase 1. The substrate sequences used for the linker sequences
are from well established caspase 1 targets, but are also cleaved by other proteases at the same amino acid
sequence. We can measure biosensor activation following the addition of inflammatory insults to cells and
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can show that caspase 1 is activated in these cells, but to claim that they are exclusively cleaved by
caspase 1 would be untrue. There are no known sequences exclusively cleaved by caspase 1. However,
these biosensors are still useful tools for studying inflammation as we can measure significant changes in
bioluminescence following activation.
A new exciting project that we are developing is a green fluorescent protein (GFP) biosensor. This
biosensor will offer a unique perspective and will add another layer to future studies. Our current
biosensors allow us to monitor at the organismal scale. That is, they allow us to look at a tissue and detect
and quantify how inflamed. However, limitations of using a luciferase readout are that single cells cannot
be observed. A GFP biosensor can give us the ability to measure inflammation in single cells.
Combination of the two biosensors will allow us to view the tissue and zoom in to see what cells
specifically in the tissue are causing the inflammation. This technology will give us a unique tool for the
further exploration of aberrant inflammatory responses.
In conclusion, our work has established multiple caspase 1 biosensors for use in vitro. Using these
biosensors, we investigated the existence of caspase 1 substrate specificity. After performing multiple
experiments, it does not appear that this is the case. However, more experiments are needed to make any
conclusions. Our new biosensors appear to be effective tools for future studies on inflammation.
Specifically, GSDMD holds great promise to become a useful tool for future studies on inflammation in
vitro as well as in vivo.
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